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Abstract: 
We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in 
therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting 
mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and 
imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical 
animal models. 
Author’s comment: 
Chronic myeloid leukaemia (CML) arises following reciprocal translocation between chromosomes 9 
and 22 (t(9;22)(q34;q11)) in a haematopoietic stem cell (HSC),  which results in the expression of the 
fusion onco-protein BCR-ABL, a constitutively active tyrosine kinase. Although BCR-ABL-specific 
tyrosine kinase inhibitors (TKIs), including first-generation imatinib, have revolutionised the 
treatment of the disease, almost two-thirds of CML patients show residual disease after five years on 
TKI treatment. This is due to the presence of TKI-insensitive leukaemic stem cells (LSCs), which is 
associated with acquired resistance and disease relapse [1]. In this context, our main aim is to find 
new therapeutic strategies to target LSCs and achieve therapy-free remission in CML patients.     
 
Recently, colleagues from the University of Glasgow and others have uncovered new molecular 
pathways involved in the survival of LSCs. These include networks regulated by c-MYC and p53 [2], 
the histone-lysine N-methyltransferase EZH2 [3] and the peroxisome proliferator-activated receptor 
gamma (PPARγ) [4]. However our study is, to our knowledge, the first to use a metabolomic-based 
approach to characterise normal human HSCs versus CML LSCs in order to find potential selective 
therapeutic targets [5]. Interestingly, the antibiotic tigecycline, shown to successfully inhibit 
mitochondrial protein translation in acute myeloid leukaemia (AML) cells [6], proved to be a 
promising candidate to target upregulated mitochondrial oxidative metabolism in CML LSCs [5]. 
 To identify metabolic vulnerabilities in CML LSCs, we compared the steady-state levels of 70 key 
metabolites of fatty acid, amino acid, glucose and energy metabolism from CML patients-derived 
CD34+ cells with their normal counterparts. We found higher levels of carnitine and acylcarnitine 
derivatives and lower levels of free fatty acids in CML CD34+ cells, suggesting a potential 
upregulation of lipolysis and fatty acid oxidation (FAO; Figure 1). Furthermore, both stable isotope-
assisted metabolomic analysis, using uniformly 13C16-labelled palmitate or 
13C16-labelled glucose, and 
functional assays measuring the oxygen consumption rate revealed a clear upregulation of the 
overall oxidative metabolism in CML CD34+ cells compared to their normal counterparts [5]. 
Interestingly, CML CD34+ cells also showed lower lactate levels and increased oxidative and 
anaplerotic activity compared to the more differentiated CD34- fraction, suggesting that primitive 
CML cells rely preferentially on oxidative metabolism rather than glycolysis [5]. Similar 13C isotopic 
enrichment experiments revealed that treatment with tigecycline reduced the amount of labelled 
carbons in tricarboxylic acid (TCA) cycle intermediates, proving that tigecycline can effectively inhibit 
the oxidative metabolism of LSCs. Our data also shows that treating CML cells with a combination of 
tigecycline and imatinib almost fully inhibits the colony formation capacity of CML progenitors and 
long-term stem cells [5]. Interestingly, the drug combination did not elicit the same effect in normal 
haematopoietic CD34+ cells, ruling out the potential for broad cytotoxicity. 
 
Importantly, as mitochondria constitute the main source of reactive oxygen species (ROS) in cells, 
our results may explain previous studies showing that LSCs present higher levels of ROS and DNA 
damage than normal HSCs [7]. Our findings indeed support the in vivo experiments results obtained 
by Bolton-Gillespie et al., which report higher levels of ROS in primitive cells compared to the more 
differentiated compartment within the bone marrow of leukaemic mice. Other studies on cancer 
stem cells, including in AML, have shown that these primitive cells rely more heavily on oxidative 
phosphorylation (OXPHOS) to supply their energetic demands compared to bulk tumour cells and 
normal stem cells, regardless of the low-ROS levels found in the more quiescent AML stem cells [8]. 
Therefore, elucidating the link between mitochondria, ROS generation and stemness in CML LSCs 
represent an attractive topic for future investigation. Lastly, using single-cell RNA sequencing 
coupled with a highly sensitive BCR-ABL detection method, Giustacchini et al. elegantly showed in a 
recent study that primitive BCR-ABL+ cells from CML patients presented an overexpression of 
OXPHOS and FAO-related genes when compared to their bystander BCR-ABL- counterparts [9]. This 
further suggests that the oxidative phenotype we characterised is specific to LSCs in patients, further 
highlighting the clinical relevance of our findings.  
 Using a well-established xenotransplant model of human CML, we also tested the effect of 
tigecycline treatment alone or in combination with imatinib in vivo. The combination treatment 
drastically reduced the number of the most primitive long-term engrafting cells. In order to 
investigate whether this combination was also effective in preventing relapse, we treated 
xenografted CML cells with tigecycline alone or in combination for a period of four weeks, then 
discontinued the treatment for two or three weeks. Strikingly, mice treated with the drug 
combination maintained a low number of LSCs after treatment discontinuation, whereas similar 
levels of LSCs were found in imatinib treated mice and untreated mice. These results reveal that 
combining tigecycline with imatinib might prevent disease relapse in CML patients with minimal 
residual disease. 
 
Taken together, these findings make a strong case for further investigation of the use of tigecycline 
in CML treatment in human, especially so as it has already been approved by the American food and 
drug administration for antibiotic use. The disappointing results from a recent phase I clinical trial 
where tigecycline was used as a single agent in relapsed or refractory AML [10] also highlights the 
relevance of the TKI combination strategy we employed in our study. Tigecycline has incidentally 
been added to the list of drug candidates in a clinical trial grant, which aims to test promising 
combinations of novel or repurposed drugs with TKIs. If results from the present study are confirmed 
in a future trial, tigecycline could represent the first step towards a real cure for CML patients and 
prove relevant in other diseases driven by OXPHOS-dependent cancer stem cells. 
Figure 1: Selective targeting of CML LSCs using tigecycline in combination with TKI 
While normal HSCs have low mitochondrial activity, transformation from a HSC to CML LSCs is 
associated with constitutive BCR-ABL kinase activity and an increase in mitochondrial oxidative 
metabolism. During the course of glycolysis, glucose is broken down to pyruvate, which can be used 
to produce lactate. Alternatively, pyruvate can be transferred to the mitochondria, where it is 
broken down in the TCA cycle. This leads to generation of reducing agents (NADH and FADH2), which 
can be used by the electron transport chain (ETC) to generate ATP. Similarly, fatty acids are activated 
(converted to fatty acyl CoA) in the cytosol and transported to the mitochondrial via the carnitine 
shuttle, where they undergo oxidation to yield acetyl-CoA for the TCA cycle. Tigecycline treatment 
inhibits OXPHOS by hindering mitochondrial translation and leads to eradication of CML LSCs, when 
used in combination with imatinib, a BCR-ABL targeting TKI. PHD, pyruvate dehydrogenase 
(transforms pyruvate into acetyl-CoA); PC, pyruvate carboxylate (catalyses anaplerotic reaction that 
creates oxaloacetate from pyruvate).  
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